Radiation therapy is frequently used to treat non-small cell lung cancers (NSCLCs). We have previously shown that a combination of ionizing radiation (IR) and the staurosporine analog PKC 412, but not Ro 31-8220, increases cell death in NSCLC cells. To identify genes involved in the enhancement of cell death, a total gene profiling in response to co-administration of (i) PKC 412 with IR, or (ii) Ro 31-8220 with IR was implemented. These combined treatments caused upregulation of 140 and 179 genes and downregulation of 253 and 425 genes, respectively. Certain genes were selected and verified by real-time quantitative PCR and, of these genes, robust suppression of Ephrin B3 expression was suggested as a possible cell death-inducing mechanism of combined treatment with IR and PKC 412. Indeed, silencing of Ephrin B3 using siRNA in NSCLC cells resulted in a major alteration of their morphology with an elongated phenotype, decreased proliferation and increased cell death signaling. Moreover, silencing of Ephrin B3 in combination with IR caused a decrease in IR-mediated G 2 -arrest, induced cellular senescence, inhibited MAPK ERK and p38 phosphorylation, and caused an upregulation of p27 kip1 expression. Finally, silencing of Ephrin B3 in combination with IR sensitized U-1810 cells to IR-induced apoptosis. In conclusion, we identify and describe Ephrin B3 as a putative signaling molecule involved in the response of NSCLC cells to combined treatment with PKC 412 and ionizing radiation.
Subject Category: Cancer
Non-small cell lung carcinoma (NSCLC) patients have a poor prognosis with a 5-year survival of about 10%. 1 Chemotherapy (CT) and radiotherapy (RT) are standard treatments for inoperable NSCLC cases but often high intrinsic resistance is encountered hampering good clinical management. Mechanisms responsible for intrinsic and acquired resistance to RT include cellular signaling alterations, for example, increased DNA repair and growth factor signaling, or impaired cell death activation. Thus we showed that impaired apoptosis signaling via the Bcl-2 family members Bak and Bax, dysfunction of the mitochondrial release of cytochrome c and subsequent effects on caspase activation, all contribute to pronounced RT resistance of NSCLC cells. [2] [3] [4] With the intention of finding treatments that could trigger cell death in ionizing radiation (IR)-resistant NSCLC cells, we showed that staurosporine could circumvent resistance and induce release of cytochrome c and subsequent caspase-3 activation. 3 Next, we examined if analogs of staurosporine, PKC 412 and Ro 31-8220, could sensitize NSCLC cells to IR. 5, 6 Indeed PKC 412 was demonstrated to sensitize for RT and triggers mitochondria-mediated apoptotic response although Ro 31-8220 did not and instead increased survival signaling.
Increased growth factor receptor signaling through, for example, EGFR has been demonstrated to influence NSCLC's response to IR (reviewed in 1 ). Treatments in which EGFR inhibitors or monoclonal antibodies, such as, cetuximab are used in combination with CT and/or RT. These treatments have unfortunately only increased survival in a small part of the patient cohort, that is, in those whose tumors have an aberrant EGFR signaling network. For the vast majority of NSCLC patients, other pathways are likely driving tumors and should be therapeutically intervened with either alone or in combination with CT/RT. In the current study, we applied a global and non-supervised strategy to explore potential key signaling events conferring RT responsiveness or resistance in NSCLC cells. Consequently, a total gene profiling of the NSCLC cell line U-1810 was carried out after IR alone or IR in combination with either PKC 412 or Ro 31-8220, using the Affymetrix-based gene array. The gene array data together with validation on gene, protein and functional levels suggested Ephrin B3, a ligand of Eph receptors (EphR), as a putative regulator of RT resistance of NSCLC cells.
Results
A combination of IR and PKC 412 increases apoptotic signaling in NSCLC cells. We previously showed that a combination of IR and PKC 412 sensitized NSCLC cells to IR-induced apoptotic cell death, 5 which was confirmed here ( Figure 1 ). Thus a combination of IR and PKC 412 triggered increased apoptototic signaling as illustrated by cleavage of PARP into the specific 85-kDa cleavage fragment (Figure 1a ), a twofold increase in caspase-mediated cleavage of cytokeratin 18 7, 8 ( Figure 1b ) and increased caspase-3 activation and apoptotic nuclear morphology (data not shown). Moreover, IR and PKC 412 combined treatment clearly caused a more prominent inhibition of proliferation than either treatment alone ( Figure 1c ).
Affymetrix-based gene array identifies genes differentially expressed in response to IR alone and to IR in combination with PKC 412 or with Ro 31-8220. To reveal genes uniquely regulated in response to a combination of IR and PKC 412, total gene profiles of U-1810 cells after exposure to IR or to IR combined with either PKC 412 or Ro 31-8220 were analyzed by Affymetrix gene array (Supplementary Figure S1A) . Thus at 24 h post IR, U-1810 cells were treated with either PKC inhibitor for 4 h and total RNA was collected. A complete list of regulated genes is found in Supplementary data (http://www.ncbi.nlm.nih.gov/ geo/, accession number AAH22499). Genes that showed at least a 1.5-fold upregulation or downregulation after IR alone or in response to a combination of IR and PKC 412 or Ro 31-8220 were selected and a two-step Venn diagram analysis was carried out as outlined (Supplementary Figure S1A) . Briefly, the differentially expressed genes in response to IR or to a single or combined treatment with either inhibitor were listed. Subsequently, the genes that showed altered expression in combinatory treatments were evaluated, generating Venn diagrams of 'unique' and 'shared' genes for the different IR combinations (Supplementary Figure S1A) . Coadministration of PKC 412 with IR was found to cause upregulation of 140 genes and downregulation of 253 genes that did not show any change in expression after the combination of IR and Ro 31-8220. Similarly, co-treatment with IR and Ro 31-8820 caused upregulation of 179 genes and downregulation of 425 genes, of which none were altered when PKC 412 was co-administrated with IR.
The differentially expressed genes were mapped onto different cellular processes using the GeneSpring GX software (Agilent Technologies, Santa Clara, CA, USA) and the gene array data filtered for genes associated with pathways known to be regulated by IR, that is, signal transduction, cell growth, cell death and cell cycle progression (Figures 2a and  b, Supplementary Tables 1-3) .
Validation of gene expression alterations by real-time quantitative PCR. A set of genes that showed at least a 1.5-fold change in expression relative to untreated U-1810 cells Figure S1B ). These genes were Ephrin B3, the regulatory B subunit of the protein phosphatase 2 gamma isoform(PPP2R2C), the estrogen receptor 1(ESR1) and a member of the RAS oncogene family Rab33A (Rab33A). RT qPCR analyses confirmed the alteration in expression of these genes although the magnitude of expression differed between this assay and gene array analyses (Figure 2c, Supplementary Figure S1B ). Importantly, a decreased protein expression of Ephrin B3 in IR and PKC 412 combined treatment was also confirmed (Figure 2d ), and Ephrin B3 was selected for validation of its role in the IR-response of NSCLC cells. [11] [12] [13] With respect to Ephrin B3, it has been demonstrated its binding to EphB3 and EphA4. The latter is a receptor that in the absence of its ligand triggers proapoptotic signaling.
14 As the role of Ephrin B3 in IR-induced signaling has not been evaluated and given the observed decreased expression of Ephrin B3 in response to the combined treatment with IR and PKC 412 (Figure 2c) , we decided to evaluate the role of Ephrin B3 in the radiosensitivity of NSCLC cells.
Consequently, Ephrin B3 was silenced using siRNA (hereafter described as Ephrin B3 siRNA) and efficient knockdown was confirmed on RNA and protein level, respectively (Figures 3a and b) . Interestingly, silencing of Ephrin B3 greatly altered appearance of U-1810 cells with morphology Figure  S2) . Moreover, in another NSCLC cell line U-1752, siRNAmediated silencing of Ephrin B3 impaired growth and induced an elongated phenotype, although this was less pronounced than in U-1810 cells (Supplementary Figure S3) .
The effect of Ephrin B3 siRNA on cell proliferation was examined using the carboxyfluorescein diacetate N-succinimidyl ester (CFSE) dye, which is diluted upon cell division and hence decreased CFSE signal indicates proliferation. Silencing of Ephrin B3 in combination with IR induced senescence of U-1810 cells. Silencing of Ephrin B3 expression caused a phenotype of U-1810 cells, which resembled senescence: a phenotype with few defined molecular alterations, but in which increased b-galactosidase activity is a surrogate marker. 16 Histochemical staining for b-galactosidase activity confirmed a senescent phenotype and about 20% of the U-1810 cells with silenced Ephrin B3 or non-target siRNA-treated and irradiated (48 h) cells were senescent (Figure 5a, right) . Importantly, silencing Ephrin B3 in combination with IR caused a more pronounced senescence phenotype with flattening and increased cell size. b-Galactosidase positivity was observed in about 40% of the cells (Figure 5a, left and right) . Figure 5b , left). Also at 48 h, post IR Ephrin B3 siRNA-treated cells showed less ERK and p38MAPK phosphorylation relative to non-target siRNAtransfected cells, an effect which was evident upon single treatment and in combination with IR (Figure 5b, left) . Thus IR resulted in a significant increase of p38 phosphorylation, which was blocked in Ephrin B3-silenced cells (Figure 5b,  left) . Similarly, silencing of Ephrin B3 was found to decrease phosphorylation of Akt at Ser473 already at time of irradiation (0 h) with an effect still evident at 48 h post IR (Figure 5b,  left) . Our results thereby demonstrate that both Akt-and MAPK-mediated survival signaling is clearly impaired upon Ephrin B3 silencing in these NSCLC cells and may in part explain the observed RT-sensitizing effect of Ephrin B3 ablation in NSCLC cells.
Silencing of
Ephrin B3 decreases MAPK ERK and p38 phosphorylation. Silencing of Ephrin B3 expression had pronounced effects on basal as well as IR-induced cell growth and cell cycle progression in NSCLC cells. We therefore analyzed how Ephrin B3 siRNA, alone or in combination with IR, influenced the phosphorylation status of growth-promoting signaling cascades, that is, p42/p44 MAPK ERK, p38MAPK, and Akt (Figure 5b, left). Interestingly, in Ephrin B3 siRNA-transfected cells, a decreased ERK and p38MAPK phosphorylation relative to non-target siRNAtransfected cells was evident at 48 h post-transfection, that is, at the time of IR (labeled 0 h;
Silencing of Ephrin B3 increases p27
Kip1 expression. Silencing of Ephrin B3 expression inhibited IR-induced G 2 /M accumulation and caused accumulation of U-1810 cells in G 0 /G 1 . We, therefore, examined molecular components involved in the regulation of these cell cycle phases, that is, p21 WAF1/Cip1 , p16
INK4A
, and p27 Kip1 , as well as cyclin B1 and phospho-cdc2 (Tyr15), the latter known to be of importance in the G 2 /M-phase progression (Figure 5b, right) . A decreased expression of p21 WAF1/Cip1 was evident in Ephrin B3-silenced cells compared with both non-irradiated and irradiated non-target siRNA-transfected cells (Figure 5b,  right) . A weak expression of p16
INK4A was observed in nontarget siRNA-expressing U-1810 cells, whereas Ephrin B3 siRNA-transfected cells did not express p16
INK4A at the time of irradiation although expression was restored at 48 h post IR (Figure 5b, right) . Interestingly, in line with an increased proportion of Ephrin B3-repressed cells in G 0 /G 1 phase, analysis of p27
Kip1 expression showed that Ephrin B3 siRNAtransfected U-1810 cells had a higher p27 kip1 expression than corresponding cells with non-target siRNA. Moreover, whereas irradiated non-target siRNA-transfected cells showed downregulation of p27 kip1 , the opposite was 
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Apoptotic morphology We also analyzed how siRNA targeting Ephrin B3 influenced expression of cyclin B1 (Figure 5b, right) . In line with the decreased number of cells in the G 2 /M phase caused by Ephrin B3 silencing, a decrease in cyclin B1 expression was observed in both untreated and irradiated cells (compare (Figure 5b, right) . Thus, these results support that Ephrin B3 silencing alters IR-induced G 2 accumulation.
Ephrin B3 silencing-mediated effects do not likely involve EphA4 receptor. Next, we examined putative Ephs involved in the effects of Ephrin B3 silencing in U-1810 NSCLC cells. Ephrin B3 is reported to be a ligand for EphA4, a dependence receptor that in absence of ligand binding activates caspase-mediated apoptotic signaling.
14 However, when the EphA4 expression was examined in these cells, only trace amounts of EphA4 was observed (Figure 5c ), making this receptor less likely to be responsible for the pronounced effects observed upon Ephrin B3 silencing. We also examined EphA4 expression after Ephrin B3 silencing but no alteration in EphA4 level was observed.
Ephrin B3 is also reported to bind EphB3 (for review see: 10 ). However, western blot analyses of the EphB3 expression in U-1810 cells showed only trace amount of this receptor (data not shown), which allows us to conclude that the primary choices for EphR binding to Ephrin B3, that is, EphA4 and EphB3, do not appear to be of major importance in NSCLC U-1810 cells. In order to understand more about the important signaling effects responsible for obtained results, we took an unbiased approach with mass spectrometry and profiled U-1810 cells with or without Ephrin B3 expression for alteration in their phosphoproteomes. 17 In these experiments the EphA2 turned out to be differentially phosphorylated on Ser897 in the presence or absence of Ephrin B3. Thus, silencing of Ephrin B3 expression caused impaired Ser897 EphA2 phosphorylation and in fact resulted in degradation of the EphA2 protein likely as a cause of inactivation of a prosurvival signaling hub controlled by Akt1, CK2, and HSP90AA1. This study strongly suggests that EphA2 is one of the corresponding receptors of Ephrin B3 in lung cancer cells. Indeed, EphA2 is highly expressed in U-1810 17 and in other NSCLC cell lines (Efazat et al., manuscript in preparation). Altering Ephrin B3 expression levels do not influence Ephrin A1 expression, another ligand for the EphA2 receptor (Figure 5c ). Yet it remains to be proven that Ephrin B3 indeed directly binds to EphA2.
Discussion
Targeted therapy directed against EGFR has had a major impact on treatment outcome for patients with an EGFRdriven LC, both as monotherapy and in combination with CT/ RT. Unfortunately, ablation of EGFR signaling is only a personalized cancer therapy for a minor fraction of NSCLC patients as the rest of the NSCLC tumors are driven by other proliferation-regulating cascades. Hence, further characterization of signaling alterations in NSCLC and how they influence the CT/RT response is needed to enable a personalized cancer therapy approach for more of the NSCLC patients. In this study, gene expression analysis of NSCLC cells refractory to RT identified Ephrin B3, a ligand of EphR, as a putative driver of RT resistance. Moreover, siRNA-mediated Ephrin B3 suppression demonstrated a role of this protein in NSCLC proliferation and cell death propensity. Importantly, ablation of Ephrin B3 altered MAPKs and Akt signaling, interfered with the IR-induced G 2 /M cell cycle arrest, increased apoptosis, mitotic catastrophe and senescence signaling and thereby increased RT sensitivity.
Binding of Ephrin to the EphR may cause activation and deactivation of the Eph and Ephrin downstream signaling cascades resulting in altered cell-to-cell interactions and cell migration. 9, 10 A critical role of the Ephrin/EphR signaling hub in tumor cell signaling is evident 9, 10, [18] [19] [20] [21] and recently certain mutations in the kinase domain or in the Ephrin ligand-binding domain of EphR's of NSCLC were described, 11 suggesting a role for EphR's signaling in this tumor type.
Here we found a novel function of Ephrin B3 in regulating tumor cell response to IR. Thus, silencing Ephrin B3 in combination with IR resulted in prominent inhibition of cell proliferation and increased apoptotic cell death. In searching for EphR involved in the effects mediated by Ephrin B3 silencing in NSCLC cells, we first focused on EphA4, a receptor previously shown to be dependent on Ephrin B3 for maintenance of survival signaling, 14 and EphB3, an Ephrin B3 binding partner. Only trace amounts of EphA4 and EphB3 were observed in NSCLC cells before and after Ephrin B3 silencing, making it unlikely that EphA4 or EphB3 has a major function in these cells. In a phosphoproteome analysis, we described that impaired Ephrin B3 expression inhibited Ser897 EphA2 phosphorylation, compromised Akt phosphorylation and caused degradation of the EphA2 receptor. 17 Therefore, we propose that Ephrin B3 mediates its RTsensitizing effects, as well as its growth inhibitory propensity, in part, by altering EphA2 signaling, although the molecular pathways require further characterization. However, in this study, we rule out that Ephrin B3 silencing would exert its effect by altering Ephrin A1 expression as it remained highly expressed when Ephrin B3 was silenced. Further work is required to pinpoint the Eph receptor binding-partners of Ephrin B3. Nevertheless, given the discovery that EphA2 is overexpressed in NSCLC and the recent data demonstrating a link between certain EphA2 mutations and NSCLC invasiveness, understanding the role of Ephrin B3 in this signaling context may provide novel therapeutic approaches for NSCLC.
Mitotic catastrophe has previously been linked to the cellular response to radiation (reviewed in 22, 23 ). We found that silencing of Ephrin B3 in combination with IR increased mitotic catastrophe in about 15% of the cells. This finding is in line with our previous publication demonstrating that a combination of PKC 412 and IR increases the number of cells undergoing mitotic catastrophe. 6 Moreover, we previously showed that mitotic catastrophe triggered by DNA-damage can, dependent on tumor cells signaling status, follow by apoptosis or necrosis. 23 With respect to Ephrin silencing in combination with IR in NSCLC U-1810 cells, the induction of mitotic catastrophe occurred independent of functional p53, a molecule previously shown to be required for efficient mitotic catastrophe.
Ephrins/EphR's are known to influence MAPKs and PI3K/ Akt signaling.
9,10 Indeed we found that Ephrin B3 siRNAtransfected U-1810 cells showed a prominent inhibition of Akt and p38MAPK, as well as p42/p44 ERK phosphorylation (Figure 5b) . Importantly, in IR-treated non-target siRNAexpressing U-1810 cells, both Akt, ERK and p38MAPK phosphorylation was evident, whereas in irradiated Ephrin B3 siRNA-expressing cells, significantly less phosphorylation was observed. Thus, our results suggest that Ephrin B3 in part regulates Akt, ERK and p38MAPK phosphorylation and it may be speculated that Ephrin B3 influences IR sensitivity in this way.
After Ephrin B3 siRNA and IR combined treatment, an elongated, flattened, and increased cell size was noted (Figure 3c ). These features are hallmarks of senescence, a form of cell death previously described as a potent barrier to tumorigenesis (reviewed in Kuilman and Peeper 24 ) . By staining the cells with b-galactosidase, a senescence effect was evident after silencing of Ephrin B3 in combination with IR (Figure 5a ). To our knowledge, this is the first observation demonstrating a role for Ephrin B3 signaling in senescence. Nevertheless, senescence factors are often used for cell-tocell communication, 24 which fits well with the bi-directional properties of Ephrin/EphR signaling. Albeit a role for p53 and Rb in senescence signaling is evident, 24 it is clear that senescence may also work in tumor cells expressing mutant p53. 25 Although the NSCLC cells used in the current experiments do not express the p53 protein, 26 Kip1 is a prerequisite or a consequence of induction of senescence after Ephrin B3 suppression.
In conclusion, in this study, we identified Ephrin B3 as a putative molecule involved in NSCLC proliferation as well as of a driver of radioresistance. Recently Eph receptor mutations in lung cancer have been identified, suggesting that the Ephrin/Eph pathways might be worth to further explore for therapeutic purposes in this tumor type. Our results suggest that interfering with Ephrin B3 binding to Eph might be a therapeutic avenue for at least certain NSCLC cases. Further work regarding Ephrin B3 and downstream signaling in NSCLC is, therefore, required to establish a therapeutic strategy with clinical potential.
Material and Methods
Cell culture, cell counting, and treatments. A human lung carcinoma cell line U-1810 derived from an undifferentiated large cell NSCLC case was used. 29 For certain experiments U-1752, a NSCLC cell line with squamous cell histology was used. 30 Both cell lines are refractory to RT with a surviving fraction 2 Gy value of about 0.9. 29, 30 All cells were maintained in RPMI 1640 medium (Sigma Aldrich, Stockholm, Sweden) supplemented with 10% heat-inactivated fetal calf serum, 1 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified incubator with 5% CO 2 . For all experiments, cells were seeded 24 h prior to the treatment at 0.5 Â 10 6 cells per 10-cm dish and were sub-confluent at time of irradiation. Irradiation was carried out at room temperature using g photons (g-IR; adsorbed dose 8 Gy, 0.9 Gy/min from a Co 60 source). At 24 h post IR, cells were pulsed with either the staurosporine analog PKC 412 (1 mM), Ro 31-8220 (10 mM) or vehicle (DMSO) for the indicated times. The PKC 412 was a gift from Novartis Pharma AG (Basel, Switzerland) and Ro 31-8220 was purchased from Sigma (Sigma Aldrich). For studies of cell morphology, photographs of cells were taken at indicated time points using an optical light microscope (Nikon Eclipse TS100, Stockholm, Sweden) at Â 400 magnification. Affymetrix gene expression analysis. RNA was isolated from 10 million U-1810 cells that were untreated or treated with PKC-412, Ro 31-8220, irradiation or a combination of IR and PKC 412 or Ro 31-8220 at the indicated time points post-treatment. The RNA was extracted using the RNeasy Mini kit, according to the manufacturer's instructions (RNeasy Midi Handbook; Qiagen, Germantown, MD, USA). The RNA purity and concentration were assessed using a NanoDrop ND-1000 UV-vis Spectrophotometer (NanoDrop Technologies Wilmington, DE, USA).
Gene expression analyses were performed using the Affymetrix platform (Affymetrix Inc., Santa Clara, CA, USA). The synthesis of cRNA, labeling and hybridization were performed according to the protocols provided by the manufacturer. The data were analyzed by the GeneSpring GX software (Agilent Technologies). Normalization of gene expression data was accomplished in two ways: per chip normalization and per gene normalization. For per chip normalization, all expression data on a chip were normalized to the 50th percentile of all values on that chip. For per gene normalization, the data for a given gene was normalized to the median expression level of that gene across all samples. The data sets were then assigned to three groups for the experiments (control, PKC 412, and Ro 31-8220 either alone or in combination with IR). The expression profiles from the three independent experiments were compared using ANOVA (parametric test, variances assumed equal) to identify genes that were differentially expressed between the different treatments. All further analyses were carried out on the remaining 863 probe sets.
Cytokeratin 18 cleavage. Caspase-mediated cytokeratin 18 cleavage is accompanied by the appearance of a specific neo-epitope in the cytokeratin 18 molecule. 7, 8, 31 An antibody that recognizes this epitope, M30 CytoDEATH-FITC antibody (Roche Diagnostics Scandinavia AB, Stockholm, Sweden), was used. 
